Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

BETHESDA, Md., April 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, filed its annual report on Form 10K today, reporting its financial results for the year ended December 31, 2012.  The report also shows strong progress in all areas of the Company's operations, enhancing the Company's leadership position in immune therapies for cancer.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

Year End 2012 Financial Results  During the twelve months ended December 31, 2012, the company used $22.8 million in cash for operating activities, compared to $14.7 million in cash for operating activities during the twelve months ended December 31, 2011.  The Company incurred an overall net loss (cash and non-cash) of $67.3 million or $5.72 per share, as compared to a net loss of $32.8 million, or $5.58 per share, for the twelve months ended December 31, 2011.

The increase in net loss was primarily due to non-cash accounting charges (i.e., inducement expense for debt reduction, amortization of prior stock issuances, beneficial conversion charges and other accounting adjustments) as well as the increased number of clinical trial sites open and recruiting across the US in the Company's Phase III clinical trial of DCVax®-L for GBM brain cancer, and expansion of the trial preparations in Europe, as noted below. 

Review of 2012 Progress Demonstrates Leadership In Immune Therapy SpaceAs described more fully below, the Company's progress during 2012 included the following:

  • major regulatory milestones in 3 countries (US, UK and Germany);
  • substantial expansion of the Company's Phase III clinical trial activities with
    '/>"/>

  • SOURCE Northwest Biotherapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
    2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
    3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
    4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
    5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
    6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
    7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
    8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
    9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
    10. Palatin Technologies To Present At The 25th Annual ROTH Conference
    11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
    (Date:10/22/2014)... 22, 2014 Grace Century, a private ... projects, announces the addition of Dr. Yousef “Josh” ... advisory team. Dr. Siddiqui will provide further healthcare expertise ... graduate of University College Medical School in ... medicine in 2001. With further certification as a General ...
    (Date:10/22/2014)... According to new market research report "Cloud ... Deployment & Support), by Service Model (SaaS, PaaS, ... (Hybrid & Community)) - Global Forecast to 2019", ... Professional Services Market into various sub-segments with an ... identifies the drivers and restraints for this market ...
    (Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
    Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3
    ... (NASDAQ: ANPI , TSX: ANP), a global ... the first New Zealand patient,was treated with Cook ... 2007. A second patient was treated in February,2008. ... stent for peripheral,arterial disease (PAD) and was recently ...
    ... Krimpets for eight-weeks; 10% of all sales ... to be ... makers of the Tastykake snack line, today announced the re-issue,of Alex,s ... one of the nation,s leading organizations in the,fight against childhood cancer. ...
    ... SOUTH SAN FRANCISCO, Calif., and SINGAPORE, April 4, ... company focused on the,discovery and development of monoclonal ... Institute (BTI), today announced a,collaboration to advance the ... the terms of the agreement, Raven will license ...
    Cached Biology Technology:Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Tasty Baking Company Continues Partnership With Alex's Lemonade Stand Foundation To Fight Childhood Cancer 2Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2
    (Date:10/22/2014)...  Leading identity analyst firm Acuity Market Intelligence forecasts ... population will have a chip-based National eID card, including ... Asia , with its vast population, ... than 60% of all National eID cards issued between ... Global National eID Industry Report: 2014 Edition" ...
    (Date:10/19/2014)... over the last 30 years contributed only marginally ... that time, according to a new study published ... "Energy access is fundamental to development: it brings ... communication, and health," says IIASA researcher Shonali Pachauri, ... access is widely agreed to be an important ...
    (Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
    Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
    ... of its kind, researchers at Queens College and Mount ... status (SES) and maternal gestational diabetes together may cause ... (ADHD) in six year olds. The data are published ... Pediatrics and Adolescent Medicine , one of the JAMA/Archives ...
    ... Group, Inc. (Pinksheets: EVRM) would like to issue the ... foremost, I want to thank our supporters; it has ... Evermedia Group, advancing the interests of wholly owned subsidiaries: ... have been fortunate to work with many outstanding professionals ...
    ... Chimpanzees, orangutans, gorillas and bonobos make more sophisticated decisions ... success, based on what they know and the likelihood to ... Daniel Haun, published on December 21 in the online journal ... human decision-making as well. The authors of the ...
    Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2The Evermedia Group 2011 Year in Review 2The Evermedia Group 2011 Year in Review 3The Evermedia Group 2011 Year in Review 4
    muscle actin (HUC1-1)...
    Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
    ... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
    ... Chicken polyclonal to Opsin 1 ( Abpromise ... Antigen: Synthetic peptide: YEDSTHASIFTYT, corresponding to amino ... and synthetic peptide corresponding to amino acids 18/30 ... and used as immunogen. Entrez ...
    Biology Products: